Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

Rhea-AI Summary

Kintara Therapeutics (Nasdaq: KTRA) will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 2:00 p.m. ET. CEO Saiid Zarrabian will deliver a corporate presentation, followed by opportunities for one-on-one meetings. Kintara focuses on developing innovative cancer therapies, with two Phase 3-ready candidates: VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. VAL-083 is a first-in-class therapy showing promise in various cancers, while REM-001 has demonstrated an 80% complete response rate in prior studies. For more details, visit www.kintara.com.

SAN DIEGO, Aug. 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that Saiid Zarrabian, Chief Executive Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9, 2021.

Mr. Zarrabian will deliver his corporate presentation on Monday, August 9, 2021 at 2:00 p.m. ET / 11:00 a.m. PT.

The live webcast will be available on the BTIG conference website at the time of the event, after which it will be available through BTIG research access.

Investors can also request a one-on-one meeting with Mr. Zarrabian to be arranged following the conclusion of the conference. Please contact a BTIG conference representative.

About Kintara

Located in San Diego, California, Kintara (Nasdaq: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

VAL-083 is a "first-in-class", small-molecule, bifunctional alkylating agent that crosses the blood-brain-barrier and has a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.

REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and Linkedin.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2020, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS
Investors
CORE IR
516-222-2560
ir@coreir.com

Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-btig-virtual-biotechnology-conference-on-august-9-2021-301348033.html

SOURCE Kintara Therapeutics

FAQ

What is Kintara Therapeutics presenting at the BTIG Virtual Biotechnology Conference?

Kintara Therapeutics will present on August 9, 2021, at 2:00 p.m. ET, focusing on their cancer therapies.

Who will represent Kintara Therapeutics at the BTIG conference?

CEO Saiid Zarrabian will represent Kintara Therapeutics at the BTIG Virtual Biotechnology Conference.

What are the two main therapies Kintara is developing?

Kintara is developing VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer.

What is the significance of VAL-083 in cancer treatment?

VAL-083 is a first-in-class therapy effective against various cancers, including glioblastoma.

What are the clinical results for REM-001?

REM-001 has shown an 80% complete response rate in patients with cutaneous metastatic breast cancer.